Was betrifft es? Warum ist das wichtig?

Safety and Protective Measures (SPM) are activities implemented without delay to ensure the protection of study participants including other involved persons against:

  • Suspected new risks that may potentially jeopardize the safety of study participants (e.g. with a negative shift in the risk-benefit ratio of the study)

 

Based on safety concerns, the implementation of SPMs are required, and must be defined and documented both HROClinO, and ClinO-MD studies. Reports should include a detailed description of the nature and circumstances that required the implementation of SPM.

 

SPM reporting requirements are based on the risk-category of the study, with category A studies reported to Swissmedic via the:

 

During study conduct, the SP-INV can decide to include a Data Safety Monitoring Board (DSMB). Based on safety risk review, the DSMB can provide support regarding the optimal implementation of SPM.

Was muss ich befolgen?

As a Project-Leader of an HRO research project, report any immediate SPMs to the Ethics Committee (EC) (via BASEC):

  • Within 7 days, and describe:
    • Circumstances that led to the implementation of SPM
    • The nature of the SPMs

 

As a Site-INV of a ClinO or ClinO-MD study, report any immediate SPM and its root cause to:

 

As a SP-INV of a ClinO or ClinO-MD study, report any immediate SPM and its root cause to:

  • Ethics Committee (EC) via BASEC, and
  • Swissmedic for risk category B and C studies within:
    • 7 days for IMP studies
    • 2 days, for IMD studies
    • 24 hours if the termination / interruption of an IMD study was due to safety reasons

 

Mehr

In the event of multi-centre EU or EEA studies, the SP-INV must also notify all other participating ECs within the same deadlines.

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – see in particular

  • Templates and checklists / Notifications

Swissmedic – see in particular

  • Human medicine
    • Clinical trials on medicinal products
    • Safety measures in clinical trials
  • Medical devices
    • Clinical trials
    • Submissions during ongoing clinical trials

References

ISO 14155:2020 Medical device (access liable to cost) – see in particular section

  • 3.46 Serious health threat

Swiss Law

ClinO – see in particular article

  • Art. 37 Notification of safety and protective measures

ClinO-MD – see in particular article

  • Art. 34 Reporting of safety and protective measures

HRO – see in particular article

  • Art. 20 Notification of safety and protective measures
Abkürzungen
  • AE – Adverse Event
  • BASEC - Business Administration System for Ethics Committees
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTU – Clinical Trials Unit
  • DSMB – Data Safety Monitoring Board
  • EC – Ethics Committee
  • EEA – European Environment Agency
  • EU – European Union
  • HRO – Human Research Ordinance
  • IMD – Investigational Medical Device
  • IMP – Investigational Medicinal Product
  • ISO - International Organization for Standardization
  • Site-INV – Site Investigator
  • SP-INV – Sponsor Investigator
  • SPM – Safety and Protective Measures
Conduct ↦ Safety ↦ Safety and Protective Measures ↦ Procedures
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Safety ↦ Safety and Protective Measures ↦ Procedures

Please note: the Easy-GCS tool is currently under construction.